<DOC>
	<DOCNO>NCT00117494</DOCNO>
	<brief_summary>In HIV hypercholesterolemic patient treat protease inhibitor , drug statin group use control cholesterol level . New potentially efficient statin may interfere protease inhibitor hence loose part activity . They thus compare establish drug class ( e.g . pravastatin ) . The protocol compare efficacy safety rosuvastatin pravastatin .</brief_summary>
	<brief_title>Rosuvastatin Versus Pravastatin HIV Patients Treated With Boosted Protease Inhibitors ( PI ) ( ANRS126 )</brief_title>
	<detailed_description>The study compare efficacy safety rosuvastatin pravastatin among dyslipidemic HIV-seropositive patient treated antiretroviral agent include boost protease inhibitor . It open , multicenter , randomise trial , two parallel group compare rosuvastatin pravastatin . Statins administer D0 , single daily dose morning , 45 consecutive day . The duration study patient 45 day include preselection period ( maximum 15 day ) . The primary end-point compare change LDL cholesterol D0 D45 , patient receive rosuvastatin ( 10 mg/day ) pravastatin ( 40 mg/day ) treat antiretroviral agent include boost Protease Inhibitor . Secondary end-points compare change triglyceride HDL cholesterol ; percentage patient normal value LDL cholesterol , HDL cholesterol triglycerides D45 ; clinical safety laboratory safety parameter rosuvastatin pravastatin ; distribution profile diameter LDL cholesterol particle . Cmin rosuvastatin , pravastatin protease inhibitor ( PI ) control D15 statin PI .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Pravastatin</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<mesh_term>HIV Protease Inhibitors</mesh_term>
	<mesh_term>Anti-Retroviral Agents</mesh_term>
	<criteria>Fasting LDL cholesterol 4.1 mmol/L ( 1.6 g/l ) Blood triglyceride 8.8 mmol/L ( 8 g/l ) HIV1 infection Viral load equal 10.000 copies/ml Stable antiretroviral regimen past two month Coronary disease Genetic muscular disease CPK 5N Hepatic renal insufficiency Alcohol intake 40g/d Hypothyroidism Pregnancy breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Hyperlipidemia</keyword>
	<keyword>HIV infection</keyword>
	<keyword>STATINS , HMG-COA</keyword>
	<keyword>Protease Inhibitor</keyword>
	<keyword>Treatment Experienced</keyword>
</DOC>